New genetics and falciparum malaria study findings recently were reported by researchers at University of Oxford

New investigation results, 'New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1,' are detailed in a study published in Infection and Immunity. According to a study from Oxford, the United Kingdom, "Although merozoite surface protein 1 (MSP-1) is a leading candidate vaccine antigen for blood-stage malaria, its efficacy in clinical trials has been limited in part by antigenic polymorphism and potentially by the inability of protein-in-adjuvant vaccines to induce strong cellular immunity. Here...

Want to see the full article?

• Purchase this article for only $3.00